Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Joint Authors
Esposito, Laure
Kamar, Nassim
Lanfranco, Luca
Joly, Melanie
Cognard, Noelle
Perrin, Peggy
Moulin, Bruno
Caillard, Sophie
Del Bello, Arnaud
Source
Case Reports in Transplantation
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-12-28
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT).
Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were treated by eculizumab after ABOi KT.
The first patient presented with features of TMA at postoperative day (POD) 13.
Because of worsening biological parameters and no recovery of kidney function, despite seven sessions of immunoadsorption, a salvage therapy of eculizumab was started on POD 23.
Kidney function slightly improved during the first 4 months after transplantation.
Eculizumab was stopped at month 4.
However, kidney function worsened progressively, leading to dialysis at month 13 after transplantation.
The second patient presented with features of TMA at POD 1.
In addition to immunoadsorption therapy, eculizumab was started on POD 6.
Kidney function improved.
Eculizumab was stopped on POD 64 and immunoadsorption sessions were stopped on POD 102.
At the last follow-up (after 9 months), eGFR was at 43 mL/min/1.73 m2.
Our case reports show the beneficial effect of eculizumab to treat ABMR after ABOi KT.
However, it should be given early after diagnosing TMA associated with ABMR.
American Psychological Association (APA)
Lanfranco, Luca& Joly, Melanie& Del Bello, Arnaud& Esposito, Laure& Cognard, Noelle& Perrin, Peggy…[et al.]. 2017. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation،Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1150409
Modern Language Association (MLA)
Lanfranco, Luca…[et al.]. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation No. 2017 (2017), pp.1-6.
https://search.emarefa.net/detail/BIM-1150409
American Medical Association (AMA)
Lanfranco, Luca& Joly, Melanie& Del Bello, Arnaud& Esposito, Laure& Cognard, Noelle& Perrin, Peggy…[et al.]. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation. 2017. Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1150409
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150409